Overview

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2026-03-30

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

Akeso

Collaborator:

Beijing Cancer Hospital